51
|
Ko CN, Zang S, Zhou Y, Zhong Z, Yang C. Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications. J Nanobiotechnology 2022; 20:380. [PMID: 35986268 PMCID: PMC9388998 DOI: 10.1186/s12951-022-01582-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 08/01/2022] [Indexed: 12/24/2022] Open
Abstract
Innate immunity is the first line of defense against invading pathogens. Innate immune cells can recognize invading pathogens through recognizing pathogen-associated molecular patterns (PAMPs) via pattern recognition receptors (PRRs). The recognition of PAMPs by PRRs triggers immune defense mechanisms and the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. However, sustained and overwhelming activation of immune system may disrupt immune homeostasis and contribute to inflammatory disorders. Immunomodulators targeting PRRs may be beneficial to treat infectious diseases and their associated complications. However, therapeutic performances of immunomodulators can be negatively affected by (1) high immune-mediated toxicity, (2) poor solubility and (3) bioactivity loss after long circulation. Recently, nanocarriers have emerged as a very promising tool to overcome these obstacles owning to their unique properties such as sustained circulation, desired bio-distribution, and preferred pharmacokinetic and pharmacodynamic profiles. In this review, we aim to provide an up-to-date overview on the strategies and applications of nanocarrier-assisted innate immune modulation for the management of infections and their associated complications. We first summarize examples of important innate immune modulators. The types of nanomaterials available for drug delivery, as well as their applications for the delivery of immunomodulatory drugs and vaccine adjuvants are also discussed.
Collapse
|
52
|
Operti MC, Bernhardt A, Pots J, Sincari V, Jager E, Grimm S, Engel A, Benedikt A, Hrubý M, De Vries IJM, Figdor CG, Tagit O. Translating the Manufacture of Immunotherapeutic PLGA Nanoparticles from Lab to Industrial Scale: Process Transfer and In Vitro Testing. Pharmaceutics 2022; 14:pharmaceutics14081690. [PMID: 36015316 PMCID: PMC9416304 DOI: 10.3390/pharmaceutics14081690] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 08/06/2022] [Accepted: 08/10/2022] [Indexed: 11/16/2022] Open
Abstract
Poly(lactic-co-glycolic acid) (PLGA) nanoparticle-based drug delivery systems are known to offer a plethora of potential therapeutic benefits. However, challenges related to large-scale manufacturing, such as the difficulty of reproducing complex formulations and high manufacturing costs, hinder their clinical and commercial development. In this context, a reliable manufacturing technique suitable for the scale-up production of nanoformulations without altering efficacy and safety profiles is highly needed. In this paper, we develop an inline sonication process and adapt it to the industrial scale production of immunomodulating PLGA nanovaccines developed using a batch sonication method at the laboratory scale. The investigated formulations contain three distinct synthetic peptides derived from the carcinogenic antigen New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) together with an invariant natural killer T-cell (iNKT) activator, threitolceramide-6 (IMM60). Process parameters were optimized to obtain polymeric nanovaccine formulations with a mean diameter of 150 ± 50 nm and a polydispersity index <0.2. Formulation characteristics, including encapsulation efficiencies, release profiles and in vitro functional and toxicological profiles, are assessed and statistically compared for each formulation. Overall, scale-up formulations obtained by inline sonication method could replicate the colloidal and functional properties of the nanovaccines developed using batch sonication at the laboratory scale. Both types of formulations induced specific T-cell and iNKT cell responses in vitro without any toxicity, highlighting the suitability of the inline sonication method for the continuous scale-up of nanomedicine formulations in terms of efficacy and safety.
Collapse
Affiliation(s)
- Maria Camilla Operti
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
- Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany
| | - Alexander Bernhardt
- Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany
| | - Jeanette Pots
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
| | - Vladimir Sincari
- Institute of Macromolecular Chemistry CAS, Heyrovsky Square 2, 162 06 Prague, Czech Republic
| | - Eliezer Jager
- Institute of Macromolecular Chemistry CAS, Heyrovsky Square 2, 162 06 Prague, Czech Republic
| | - Silko Grimm
- Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany
| | - Andrea Engel
- Evonik Corporation, Birmingham Laboratories, Birmingham, AL 35211, USA
| | - Anne Benedikt
- Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany
| | - Martin Hrubý
- Institute of Macromolecular Chemistry CAS, Heyrovsky Square 2, 162 06 Prague, Czech Republic
| | - Ingrid Jolanda M. De Vries
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
| | - Carl G. Figdor
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
| | - Oya Tagit
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
- Correspondence:
| |
Collapse
|
53
|
Alesci A, Gitto M, Kotańska M, Lo Cascio P, Miller A, Nicosia N, Fumia A, Pergolizzi S. Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. Hum Immunol 2022; 83:755-767. [PMID: 35963787 PMCID: PMC9359511 DOI: 10.1016/j.humimm.2022.08.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Revised: 07/10/2022] [Accepted: 08/03/2022] [Indexed: 12/15/2022]
Abstract
In December 2019, a new single-stranded RNA coronavirus, SARS-CoV-2, appeared in China and quickly spread around the world leading to a pandemic. Infection with SARS-CoV-2 generates symptoms ranging from asymptomatic to severe, occasionally requiring hospitalization in intensive care units, and, in more severe cases, leading to death. Scientists and researchers around the world have made a real race against time to develop various vaccines to slow down and stop the spread of the virus. In addition to conventional viral vector vaccines, new generation mRNA vaccines, BNT152b2 (Comirnaty) and mRNA-1273 (Spikevax), have been developed respectively by Pfizer/BioNTech and Moderna. These vaccines act on immune cells to induce an immune response with the production of specific antibodies against Spike protein of SARS-CoV-2, and to stimulate the differentiation of T and B memory cells. The objective of this review is to provide a detailed picture of the validity of these new vaccines and the safety of vaccination. Not only was the immunogenic effect of mRNA vaccines evaluated, but also the psychosocial impact they had on the population. The data collected show that this type of vaccine can also be an excellent candidate for future treatment and eradication of possible new pathologies with viral and non-viral etiology.
Collapse
Affiliation(s)
- Alessio Alesci
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.
| | - Marco Gitto
- Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; Phoniatric Unit, Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, 20157 Milan, Italy.
| | - Magdalena Kotańska
- Department of Pharmacological Screening, Jagiellonian University, Medical College, PL 30-688 Cracow, Poland.
| | - Patrizia Lo Cascio
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.
| | - Anthea Miller
- Department of Veterinary Sciences, University of Messina, Polo Universitario dell'Annunziata, 98168 Messina, Italy.
| | - Noemi Nicosia
- Department of Pharmacological Screening, Jagiellonian University, Medical College, PL 30-688 Cracow, Poland; Division of Neuroscience, Vita Salute San Raffaele University, 20132, Milan, Italy.
| | - Angelo Fumia
- Department of Clinical and Experimental Medicine, University of Messina, Padiglione C, A. O. U. Policlinico "G. Martino", 98147 Messina, Italy.
| | - Simona Pergolizzi
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.
| |
Collapse
|
54
|
Javan Nikkhah S, Thompson D. Copolyelectrolyte-Based Nanocapsules for Oral Monoclonal Antibody Therapy: A Mesoscale Modeling Survey. Biomacromolecules 2022; 23:3875-3886. [PMID: 35916698 DOI: 10.1021/acs.biomac.2c00699] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Antibody therapy generally requires parenteral injection to attain the required bioavailability and pharmacokinetics, but improved formulations may slow enzymatic degradation of the antibody in the gastrointestinal tract, permitting the use of noninvasive oral delivery. Rationally designed carrier materials can potentially improve therapeutic activity both by shielding fragile biopharmaceuticals from proteolytic degradation and targeting specific receptors in vivo. One potentially useful class of protein carriers is block copolyelectrolytes, one polyelectrolyte plus one neutral hydrophilic polymer block, that self-assemble into stable micelles, providing a simple and biocompatible nanocapsule separating the protein from the outer medium. Here, we develop and implement an integrated mesoscale model to design molecular structures for block copolyelectrolyte nanocapsules predicted to protect Trastuzumab, an antibody used to treat breast cancer, in the low pH gastrointestinal tract and to selectively release this antibody in the more neutral intestinal environment. The simulations show a tightly packed self-assembled core-shell structure at pH = 3 that is ruptured and dynamically reassembled into a weaker structure at pH = 7. Our model identifies that the designed block copolyelectrolyte characteristics, such as block length ratio, can control the level of drug protection and release in vivo, providing simple design rules for engineering polyelectrolyte-based formulations that may allow oral administration of targeted antibody chemotherapies.
Collapse
Affiliation(s)
- Sousa Javan Nikkhah
- Department of Physics, Bernal Institute, University of Limerick, V94 T9PX Limerick, Republic of Ireland.,Department of Chemical Sciences, Bernal Institute, University of Limerick, Limerick V94 T9PX, Republic of Ireland
| | - Damien Thompson
- Department of Physics, Bernal Institute, University of Limerick, V94 T9PX Limerick, Republic of Ireland
| |
Collapse
|
55
|
Younis NK, Roumieh R, Bassil EP, Ghoubaira JA, Kobeissy F, Eid AH. Nanoparticles: attractive tools to treat colorectal cancer. Semin Cancer Biol 2022; 86:1-13. [DOI: 10.1016/j.semcancer.2022.08.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 08/17/2022] [Accepted: 08/19/2022] [Indexed: 10/31/2022]
|
56
|
Goharshadi EK, Goharshadi K, Moghayedi M. The use of nanotechnology in the fight against viruses: A critical review. Coord Chem Rev 2022. [DOI: 10.1016/j.ccr.2022.214559] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
57
|
Moshref Javadi M, Taghdisi Hosseinzadeh M, Soliemani N, Rommasi F. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2. Microb Pathog 2022; 170:105687. [PMID: 35917987 PMCID: PMC9339102 DOI: 10.1016/j.micpath.2022.105687] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 03/31/2022] [Accepted: 07/19/2022] [Indexed: 11/29/2022]
Abstract
Background and Introduction: SARS-CoV-2 is currently considered as the most challenging issue in the field of health and medicine by causing a global pandemic. Vaccines are counted as a promising candidate to terminate this deadly pandemic. Various structural proteins in SARS-CoV-2 have recently drawn attention to be utilized as candidate vaccines to stimulate immune responses against COVID-19. Materials and methods In current study, the RBD protein was cloned and expressed in E. coli host. Then, the expressed RBD protein was purified and its characterizations were evaluated through various methods. Gold nanoparticles, which were utilized as a carrier for candidate Nano-vaccine, were synthesized via oxidation-reduction reaction. While Gold NPs-conjugated RBD was injected into the second treatment group, in the first candidate vaccine, RBD was injected into the first treatment group solely. Complete and Incomplete Freud's Adjuvant were also utilized for both treatment groups to enhance the immune responses against RBD antigen. Immunizations were repeated 2 times in 14-day intervals to boost the immune system of BALB/c mice. The humoral and cell-mediated immune responses were examined through immune and cytokine assays. Results Our outcomes demonstrate that strong short-term humoral immunity (IgM) was induced in both the first and second treatment group, while long-term humoral responses (IgG) were only observed in the second treatment group. While stronger short- and long-term humoral (IgM and IgG, respectively) were observed in the second treatment group, particular cytokines production (TNF-ɑ and IFN-γ) as a marker of cell-mediated responses were significantly higher in the first treatment group. Discussion and conclusion Our study results show the high potentiality of RBD protein as an appropriate stimulating antigen in vaccine synthesis and testifies RBD-based candidate vaccines to control the COVID-19 pandemic. Our outcomes also recommend that Nano-vaccines can be more suitable candidates when stronger long-term immune responses matter.
Collapse
Affiliation(s)
- Mahtab Moshref Javadi
- Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
| | - Mozhgan Taghdisi Hosseinzadeh
- Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
| | - Neda Soliemani
- Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
| | - Foad Rommasi
- Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
| |
Collapse
|
58
|
Messerian KO, Zverev A, Kramarczyk JF, Zydney AL. Pressure-dependent fouling behavior during sterile filtration of mRNA-containing lipid nanoparticles. Biotechnol Bioeng 2022; 119:3221-3229. [PMID: 35906785 DOI: 10.1002/bit.28200] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 07/25/2022] [Accepted: 07/26/2022] [Indexed: 11/11/2022]
Abstract
The COVID-19 pandemic has generated growing interest in the development of mRNA-based vaccines and therapeutics. However, the size and properties of the lipid nanoparticles (LNPs) used to deliver the nucleic acids can lead to unique phenomena during manufacturing that are not typical of other biologics. The objective of this study was to develop a more fundamental understanding of the factors controlling the performance of sterile filtration of mRNA-LNPs. Experimental filtration studies were performed with a Moderna mRNA-LNP solution using a commercially available dual-layer polyethersulfone sterile filter, the Sartopore 2 XLG. Unexpectedly, increasing the transmembrane pressure (TMP) from 2 to 20 psi provided more than a two-fold increase in filter capacity. Also surprisingly, the effective resistance of the fouled filter decreased with increasing TMP, in contrast to the pressure-independent behavior expected for an incompressible media and the increase in resistance typically seen for a compressible fouling deposit. The mRNA-LNPs appear to foul the dual-layer filter by blocking the pores in the downstream sterilizing-grade membrane layer, as demonstrated both by scanning electron microscopy (SEM) and derivative analysis of filtration data collected for the two layers independently. These results provide important insights into the mechanisms governing the filtration of mRNA-LNP vaccines and therapeutics. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Kevork Oliver Messerian
- Department of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802
| | | | | | - Andrew L Zydney
- Department of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802
| |
Collapse
|
59
|
Development of a rapid in vitro pre-screen for distinguishing effective liposome-adjuvant delivery systems. Sci Rep 2022; 12:12448. [PMID: 35859154 PMCID: PMC9299755 DOI: 10.1038/s41598-022-14449-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 06/06/2022] [Indexed: 01/07/2023] Open
Abstract
Liposomes are a strong supporting tool in vaccine technology, as they are a versatile system that not only act as antigen delivery systems but also adjuvants that can be highly effective at stimulating both innate and adaptive immune responses. Their ability to induce cell-mediated immunity makes their use in vaccines a useful tool in the development of novel, more effective vaccines against intracellular infections (e.g. HIV, malaria and tuberculosis). Currently, screening of novel liposome formulations uses murine in vivo models which generate data that often correlates poorly with human data. In addition, these models are both high cost and low throughput, making them prohibitive for large scale screening of formulation libraries. This study uses the cationic liposome formulation DDA:TDB (known as cationic adjuvant formulation 01 (CAF01)), as a lead formulation, along with other liposome formulations of known in vivo efficacy to develop an in vitro screening tool for liposome formulation development. THP-1-derived macrophages were the model antigen presenting cell used to assess the ability of the liposome formulations to attract, associate with and activate antigen presenting cells in vitro, crucial steps necessary for an effective immune response to antigen. By using a combination of in vitro functions, the study highlights the potential use of an in vitro screening tool, to predict the in vivo efficacy of novel liposome formulations. CAF01 was predicted as the most effective liposome formulation when assessing all in vitro functions and a measure of in vitro activation was able to predict 80% of the liposome correctly for their ability to induce an in vivo IFN-ү response.
Collapse
|
60
|
Wilson B, Mukundan Geetha K. Nanomedicine to deliver biological macromolecules for treating COVID-19. Vaccine 2022; 40:3931-3941. [PMID: 35660038 PMCID: PMC9149150 DOI: 10.1016/j.vaccine.2022.05.068] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 03/21/2022] [Accepted: 05/19/2022] [Indexed: 12/15/2022]
Abstract
Coronavirus disease (COVID-19) was first reported in December 2019, China and later it was found that the causative microorganism is severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As on 3rd June 2021, SARS-CoV-2 has affected 171049741 people worldwide with 3549710 deaths. Nanomedicine such as nanoparticles, liposomes, lipid nanoparticles, virus-like nanoparticles offer tremendous hopes to treat viral infections including COVID-19. Most importantly target specific ligands can be attached on the surface of them and this makes them more target specific and the loaded drug can be delivered to cellular and molecular level. These properties of nanomedicines can be utilized to deliver drugs or vaccines to treat viral diseases including SARS-CoV-2 infection. This review discusses about SARS-CoV-2 and the potential application of nanomedicines for delivering biological macromolecules like vaccines and drugs for treating COVID-19.
Collapse
Affiliation(s)
- Barnabas Wilson
- Department of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Kumaraswamy Layout, Bangalore, Karnataka 560078, India.
| | - Kannoth Mukundan Geetha
- Department of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University, Kumaraswamy Layout, Bangalore, Karnataka 560078, India
| |
Collapse
|
61
|
Mathur D, Rogers KE, Díaz SA, Muroski ME, Klein WP, Nag OK, Lee K, Field LD, Delehanty JB, Medintz IL. Determining the Cytosolic Stability of Small DNA Nanostructures In Cellula. NANO LETTERS 2022; 22:5037-5045. [PMID: 35580267 PMCID: PMC9233082 DOI: 10.1021/acs.nanolett.2c00917] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
DNA nanostructures have proven potential in biomedicine. However, their intracellular interactions─especially cytosolic stability─remain mostly unknown and attempts to discern this are confounded by the complexities of endocytic uptake and entrapment. Here, we bypass the endocytic uptake and evaluate the DNA structural stability directly in live cells. Commonly used DNA structures─crosshairs and a tetrahedron─were labeled with a multistep Förster resonance energy transfer dye cascade and microinjected into the cytosol of transformed and primary cells. Energy transfer loss, as monitored by fluorescence microscopy, reported the structure's direct time-resolved breakdown in cellula. The results showed rapid degradation of the DNA crosshair within 20 min, while the tetrahedron remained consistently intact for at least 1 h postinjection. Nuclease assays in conjunction with a current understanding of the tetrahedron's torsional rigidity confirmed its higher stability. Such studies can inform design parameters for future DNA nanostructures where programmable degradation rates may be required.
Collapse
Affiliation(s)
- Divita Mathur
- College of Science, George Mason University, Fairfax, Virginia 22030, United States
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
| | - Katherine E Rogers
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
- Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States
| | - Sebastián A Díaz
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
| | - Megan E Muroski
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
- American Society of Engineering Education, Washington, DC 20036, United States
| | - William P Klein
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
- National Research Council, Washington, DC 20001, United States
| | - Okhil K Nag
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
| | - Kwahun Lee
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
- American Society of Engineering Education, Washington, DC 20036, United States
| | - Lauren D Field
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
- National Research Council, Washington, DC 20001, United States
| | - James B Delehanty
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
| | - Igor L Medintz
- Center for Bio/Molecular Science and Engineering Code 6900, US Naval Research Laboratory, Washington, DC 20375, United States
| |
Collapse
|
62
|
In-Silico Design of a Multi‑epitope Construct Against Influenza A Based on Nucleoprotein Gene. Int J Pept Res Ther 2022. [DOI: 10.1007/s10989-022-10418-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
63
|
Chandrasekar V, Singh AV, Maharjan RS, Dakua SP, Balakrishnan S, Dash S, Laux P, Luch A, Singh S, Pradhan M. Perspectives on the Technological Aspects and Biomedical Applications of Virus‐Like Particles/Nanoparticles in Reproductive Biology: Insights on the Medicinal and Toxicological Outlook. ADVANCED NANOBIOMED RESEARCH 2022. [DOI: 10.1002/anbr.202200010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Affiliation(s)
| | - Ajay Vikram Singh
- German Federal Institute for Risk Assessment (BfR) Department of Chemical and Product Safety Max-Dohrn-Straße 8-10 10589 Berlin Germany
| | - Romi Singh Maharjan
- German Federal Institute for Risk Assessment (BfR) Department of Chemical and Product Safety Max-Dohrn-Straße 8-10 10589 Berlin Germany
| | | | | | - Sagnika Dash
- Obstetrics and Gynecology Apollo Clinic Qatar 23656 Doha Qatar
| | - Peter Laux
- German Federal Institute for Risk Assessment (BfR) Department of Chemical and Product Safety Max-Dohrn-Straße 8-10 10589 Berlin Germany
| | - Andreas Luch
- German Federal Institute for Risk Assessment (BfR) Department of Chemical and Product Safety Max-Dohrn-Straße 8-10 10589 Berlin Germany
| | - Suyash Singh
- Department of Neurosurgery All India Institute of Medical Sciences Raebareli UP 226001 India
| | - Mandakini Pradhan
- Department of Fetal Medicine Sanjay Gandhi Post Graduate Institute of Medical Sciences Reabareli Road Lucknow UP 226014 India
| |
Collapse
|
64
|
Kiremitler NB, Kemerli MZ, Kayaci N, Karagoz S, Pekdemir S, Sarp G, Sanduvac S, Onses MS, Yilmaz E. Nanostructures for the Prevention, Diagnosis, and Treatment of SARS-CoV-2: A Review. ACS APPLIED NANO MATERIALS 2022; 5:6029-6054. [PMID: 37552745 PMCID: PMC8905929 DOI: 10.1021/acsanm.2c00181] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Accepted: 02/15/2022] [Indexed: 06/17/2023]
Abstract
Scientists, doctors, engineers, and even entire societies have become aware of the seriousness of the COVID-19 infection and are taking action quickly, using all the tools from protection to treatment against coronavirus SARS-CoV-2. Especially in this sense, scientific approaches and materials using nanotechnology are frequently preferred. In this review, we focus on how nanoscience and nanotechnology approaches can be used for protective equipment, diagnostic and treatment methods, medicine, and vaccine applications to stop the coronavirus SARS-CoV-2 and prevent its spread. SARS-CoV-2, which itself can be considered as a core-shell nanoparticle, can interact with various materials around it and remain bound for variable periods of time while maintaining its bioactivity. These applications are especially critical for the controlled use of disinfection systems. One of the most important processes in the fight against coronavirus is the rapid diagnosis of the virus in humans and the initiation of isolation and treatment processes. The development of nanotechnology-based test and diagnostic kits is another important research thrust. Nanotechnological therapeutics based on antiviral drug design and nanoarchitecture vaccines have been vital. Nanotechnology plays critical roles in the production of protective film surfaces for self-cleaning and antiviral masks, gloves, and laboratory clothes. An overview of literature studies highlighting nanotechnology and nanomaterial-based approaches to combat SARS-CoV-2 is presented.
Collapse
Affiliation(s)
- Nuri Burak Kiremitler
- ERNAM-Erciyes University Nanotechnology
Application and Research Center, 38039 Kayseri,
Turkey
- Department of Materials Science and Engineering,
Faculty of Engineering, Erciyes University, 38039 Kayseri,
Turkey
| | - Munteha Zeynep Kemerli
- Drug Application and Research Center,
Erciyes University, 38039 Kayseri,
Turkey
- Department of Health Services, Halil Bayraktar
Vocational College, Erciyes University, 38039 Kayseri,
Turkey
| | - Nilgun Kayaci
- ERNAM-Erciyes University Nanotechnology
Application and Research Center, 38039 Kayseri,
Turkey
- Department of Materials Science and Engineering,
Faculty of Engineering, Erciyes University, 38039 Kayseri,
Turkey
| | - Sultan Karagoz
- ERNAM-Erciyes University Nanotechnology
Application and Research Center, 38039 Kayseri,
Turkey
- Department of Textile Engineering, Faculty of
Engineering, Erciyes University, 38039 Kayseri,
Turkey
| | - Sami Pekdemir
- ERNAM-Erciyes University Nanotechnology
Application and Research Center, 38039 Kayseri,
Turkey
- Department of Airframes and Powerplants, Erciyes
University, 38039 Kayseri, Turkey
| | - Gokhan Sarp
- ERNAM-Erciyes University Nanotechnology
Application and Research Center, 38039 Kayseri,
Turkey
- Faculty of Pharmacy, Erciyes
University, 38039 Kayseri, Turkey
| | - Senem Sanduvac
- ERNAM-Erciyes University Nanotechnology
Application and Research Center, 38039 Kayseri,
Turkey
- Bünyan Vocational College, Kayseri
University, 38280 Kayseri, Turkey
| | - Mustafa Serdar Onses
- ERNAM-Erciyes University Nanotechnology
Application and Research Center, 38039 Kayseri,
Turkey
- Department of Materials Science and Engineering,
Faculty of Engineering, Erciyes University, 38039 Kayseri,
Turkey
| | - Erkan Yilmaz
- ERNAM-Erciyes University Nanotechnology
Application and Research Center, 38039 Kayseri,
Turkey
- Faculty of Pharmacy, Erciyes
University, 38039 Kayseri, Turkey
- Technology Research & Application
Center (TAUM), Erciyes University, 38039 Kayseri,
Turkey
- ChemicaMed Chemical Inc., Erciyes
University Technology Development Zone, 38039 Kayseri,
Turkey
| |
Collapse
|
65
|
Loutfy SA, Abdel-Salam AI, Moatasim Y, Gomaa MR, Abdel Fattah NF, Emam MH, Ali F, ElShehaby HA, Ragab EA, Alam El-Din HM, Mostafa A, Ali MA, Kasry A. Antiviral activity of chitosan nanoparticles encapsulating silymarin (Sil-CNPs) against SARS-CoV-2 ( in silico and in vitro study). RSC Adv 2022; 12:15775-15786. [PMID: 35685696 PMCID: PMC9132606 DOI: 10.1039/d2ra00905f] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Accepted: 05/19/2022] [Indexed: 02/06/2023] Open
Abstract
To develop a specific treatment against COVID-19, we investigated silymarin–chitosan nanoparticles (Sil–CNPs) as an antiviral agent against SARS-CoV-2 using in silico and in vitro approaches. Docking of Sil and CNPs was carried out against SARS-CoV-2 spike protein using AutoDock Vina. CNPs and Sil–CNPs were prepared by the ionic gelation method and characterized by TEM, FT-IR, zeta analysis, and the membrane diffusion method to determine the drug release profile. Cytotoxicity was tested on both Vero and Vero E6 cell lines using the MTT assay. Minimum binding energies with spike protein and ACE2 were −6.6, and −8.0 kcal mol−1 for CNPs, and −8.9, and −9.7 kcal mol−1 for Sil, respectively, compared to −6.6 and −8.4 kcal mol−1 respectively for remdesivir (RMV). CNPs and Sil–CNPs were prepared at sizes of 29 nm and 82 nm. The CC50 was 135, 35, and 110 μg mL−1 for CNPs, Sil, and Sil–CNPs, respectively, on Vero E6. The IC50 was determined at concentrations of 0.9, 12 and 0.8 μg mL−1 in virucidal/replication assays for CNPs, Sil, and Sil–CNPs respectively using crystal violet. These results indicate antiviral activity of Sil–CNPs against SARS-CoV-2. To develop a specific treatment against COVID-19, we investigated silymarin–chitosan nanoparticles (Sil–CNPs) as an antiviral agent against SARS-CoV-2 using in silico and in vitro approaches.![]()
Collapse
Affiliation(s)
- Samah A Loutfy
- Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute (NCI), Cairo University Fom El-Khalig 11796 Cairo Egypt .,Nanotechnology Research Center (NTRC), The British University in Egypt El-Shorouk City, Suez Desert Road P. O. Box 43 Cairo 11837 Egypt
| | - Ahmed I Abdel-Salam
- Nanotechnology Research Center (NTRC), The British University in Egypt El-Shorouk City, Suez Desert Road P. O. Box 43 Cairo 11837 Egypt
| | - Yassmin Moatasim
- Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC) Giza 12622 Egypt
| | - Mokhtar R Gomaa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC) Giza 12622 Egypt
| | - Nasra F Abdel Fattah
- Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute (NCI), Cairo University Fom El-Khalig 11796 Cairo Egypt
| | - Merna H Emam
- Nanotechnology Research Center (NTRC), The British University in Egypt El-Shorouk City, Suez Desert Road P. O. Box 43 Cairo 11837 Egypt
| | - Fedaa Ali
- Nanotechnology Research Center (NTRC), The British University in Egypt El-Shorouk City, Suez Desert Road P. O. Box 43 Cairo 11837 Egypt
| | | | - Eman A Ragab
- Biochemistry Dept, Faculty of Science, Cairo University Egypt
| | - Hanaa M Alam El-Din
- Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute (NCI), Cairo University Fom El-Khalig 11796 Cairo Egypt
| | - Ahmed Mostafa
- Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC) Giza 12622 Egypt
| | - Mohamed A Ali
- Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC) Giza 12622 Egypt
| | - Amal Kasry
- Nanotechnology Research Center (NTRC), The British University in Egypt El-Shorouk City, Suez Desert Road P. O. Box 43 Cairo 11837 Egypt
| |
Collapse
|
66
|
Juneja M, Suthar T, Pardhi VP, Ahmad J, Jain K. Emerging trends and promises of nanoemulsions in therapeutics of infectious diseases. Nanomedicine (Lond) 2022; 17:793-812. [PMID: 35587031 DOI: 10.2217/nnm-2022-0006] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Infectious diseases are prevalent and have contributed to high morbidity rates by creating havoc like the COVID-19, 1918 influenza and Black Death (the plague) pandemics. Antimicrobial resistance, adverse effects, the emergence of co-infections and the high cost of antimicrobial therapies are major threats to the health of people worldwide while impacting overall healthcare and socioeconomic development. One of the most common ways to address this issue lies in improving existing antimicrobial drug-delivery systems. Nanoemulsions and their modified forms have been successfully employed for the delivery of antimicrobials to treat infectious diseases. In this article, the authors comprehensively reviewed how nanoemulsion-based formulation systems are shifting the paradigm for therapeutics and diagnosis of infectious diseases.
Collapse
Affiliation(s)
- Mehak Juneja
- Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER)-Raebareli, Uttar Pradesh, 226002, India
| | - Teeja Suthar
- Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER)-Raebareli, Uttar Pradesh, 226002, India
| | - Vishwas P Pardhi
- Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER)-Raebareli, Uttar Pradesh, 226002, India
| | - Javed Ahmad
- Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, 11001, Saudi Arabia
| | - Keerti Jain
- Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER)-Raebareli, Uttar Pradesh, 226002, India
| |
Collapse
|
67
|
Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges. Pharmaceutics 2022; 14:pharmaceutics14051066. [PMID: 35631652 PMCID: PMC9144974 DOI: 10.3390/pharmaceutics14051066] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 04/27/2022] [Accepted: 05/09/2022] [Indexed: 12/12/2022] Open
Abstract
To prevent the coronavirus disease 2019 (COVID-19) pandemic and aid restoration to prepandemic normality, global mass vaccination is urgently needed. Inducing herd immunity through mass vaccination has proven to be a highly effective strategy for preventing the spread of many infectious diseases, which protects the most vulnerable population groups that are unable to develop immunity, such as people with immunodeficiencies or weakened immune systems due to underlying medical or debilitating conditions. In achieving global outreach, the maintenance of the vaccine potency, transportation, and needle waste generation become major issues. Moreover, needle phobia and vaccine hesitancy act as hurdles to successful mass vaccination. The use of dissolvable microneedles for COVID-19 vaccination could act as a major paradigm shift in attaining the desired goal to vaccinate billions in the shortest time possible. In addressing these points, we discuss the potential of the use of dissolvable microneedles for COVID-19 vaccination based on the current literature.
Collapse
|
68
|
Sepand MR, Bigdelou B, Ho JQ, Sharaf M, Lannigan AJ, Sullivan IM, da Silva AP, Barrett LO, McGoldrick S, Lnu Y, Lynch SE, Boisclair JM, Barnard-Pratt DD, Zanganeh S. Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines. Antibodies (Basel) 2022; 11:35. [PMID: 35645208 PMCID: PMC9149948 DOI: 10.3390/antib11020035] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 05/01/2022] [Accepted: 05/06/2022] [Indexed: 12/04/2022] Open
Abstract
Questions and concerns regarding the efficacy and immunogenicity of coronavirus disease 2019 (COVID-19) vaccines have plagued scientists since the BNT162b2 mRNA vaccine was introduced in late 2020. As a result, decisions about vaccine boosters based on breakthrough infection rates and the decline of antibody titers have commanded worldwide attention and research. COVID-19 patients have displayed continued severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-spike-protein-specific antibodies and neutralizing antibodies in longitudinal studies; in addition, cytokine activation has been detected at early steps following SARS-CoV-2 infection. Epitopes that are highly reactive and can mediate long-term antibody responses have been identified at the spike and ORF1ab proteins. The N-terminal domain of the S1 and S2 subunits is the location of important SARS-CoV-2 spike protein epitopes. High sequence identity between earlier and newer variants of SARS-CoV-2 and different degrees of sequence homology among endemic human coronaviruses have been observed. Understanding the extent and duration of protective immunity is consequential for determining the course of the COVID-19 pandemic. Further knowledge of memory responses to different variants of SARS-CoV-2 is needed to improve the design of the vaccine.
Collapse
Affiliation(s)
- Mohammad Reza Sepand
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Banafsheh Bigdelou
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Jim Q Ho
- Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
| | - Mohammad Sharaf
- Department of Chemical and Biomolecular Engineering, New York University, New York, NY 10012, USA
| | - Alexis J Lannigan
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Ian M Sullivan
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Alecsander P da Silva
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Leland O Barrett
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Scott McGoldrick
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Yuvraj Lnu
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Shannon E Lynch
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Jared M Boisclair
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Dakarai D Barnard-Pratt
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| | - Steven Zanganeh
- Department of Bioengineering, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA
| |
Collapse
|
69
|
Dzuvor CKO, Tettey EL, Danquah MK. Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2022; 14:e1785. [PMID: 35238490 PMCID: PMC9111085 DOI: 10.1002/wnan.1785] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 02/02/2022] [Accepted: 02/07/2022] [Indexed: 12/13/2022]
Abstract
The emergence of SARS‐COV‐2, the causative agent of new coronavirus disease (COVID‐19) has become a pandemic threat. Early and precise detection of the virus is vital for effective diagnosis and treatment. Various testing kits and assays, including nucleic acid detection methods, antigen tests, serological tests, and enzyme‐linked immunosorbent assay (ELISA), have been implemented or are being explored to detect the virus and/or characterize cellular and antibody responses to the infection. However, these approaches have inherent drawbacks such as nonspecificity, high cost, are characterized by long turnaround times for test results, and can be labor‐intensive. Also, the circulating SARS‐COV‐2 variant of concerns, reduced antibody sensitivity and/or neutralization, and possible antibody‐dependent enhancement (ADE) have warranted the search for alternative potent therapeutics. Aptamers, which are single‐stranded oligonucleotides, generated artificially by SELEX (Evolution of Ligands by Exponential Enrichment) may offer the capacity to generate high‐affinity neutralizers and/or bioprobes for monitoring relevant SARS‐COV‐2 and COVID‐19 biomarkers. This article reviews and discusses the prospects of implementing aptamers for rapid point‐of‐care detection and treatment of SARS‐COV‐2. We highlight other SARS‐COV‐2 targets (N protein, spike protein stem‐helix), SELEX augmented with competition assays and in silico technologies for rapid discovery and isolation of theranostic aptamers against COVID‐19 and future pandemics. It further provides an overview on site‐specific bioconjugation approaches, customizable molecular scaffolding strategies, and nanotechnology platforms to engineer these aptamers into ultrapotent blockers, multivalent therapeutics, and vaccines to boost both humoral and cellular immunity against the virus. This article is categorized under:Therapeutic Approaches and Drug Discovery > Emerging Technologies Diagnostic Tools > Biosensing Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease
Collapse
Affiliation(s)
- Christian K O Dzuvor
- Bioengineering Laboratory, Department of Chemical and Biological Engineering, Monash University, Clayton, Victoria, Australia
| | | | - Michael K Danquah
- Department of Chemical Engineering, University of Tennessee, Chattanooga, Tennessee, USA
| |
Collapse
|
70
|
Nwagwu CS, Ugwu CN, Ogbonna JDN, Onugwu AL, Agbo CP, Echezona AC, Ezeibe EN, Uzondu S, Kenechukwu FC, Akpa PA, Momoh MA, Nnamani PO, Tarirai C, Ofokansi KC, Attama AA. Recent and advanced nano-technological strategies for COVID-19 vaccine development. METHODS IN MICROBIOLOGY 2022; 50:151-188. [PMID: 38620863 PMCID: PMC9015106 DOI: 10.1016/bs.mim.2022.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The outbreak of the COVID-19 pandemic in 2019 has been one of the greatest challenges modern medicine and science has ever faced. It has affected millions of people around the world and altered human life and activities as we once knew. The high prevalence as well as an extended period of incubations which usually does not present with symptoms have played a formidable role in the transmission and infection of millions. A lot of research has been carried out on developing suitable treatment and effective preventive measures for the control of the pandemic. Preventive strategies which include social distancing, use of masks, washing of hands, and contact tracing have been effective in slowing the spread of the virus; however, the infectious nature of the SARS-COV-2 has made these strategies unable to eradicate its spread. In addition, the continuous increase in the number of cases and death, as well as the appearance of several variants of the virus, has necessitated the development of effective and safe vaccines in a bid to ensure that human activities can return to normalcy. Nanotechnology has been of great benefit in the design of vaccines as nano-sized materials have been known to aid the safe and effective delivery of antigens as well as serve as suitable adjuvants to potentiate responses to vaccines. There are only four vaccine candidates currently approved for use in humans while many other candidates are at various levels of development. This review seeks to provide updated information on the current nano-technological strategies employed in the development of COVID-19 vaccines.
Collapse
Affiliation(s)
- Chinekwu Sherridan Nwagwu
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Chinenye Nnenna Ugwu
- Department of Pharmaceutical Microbiology and Biotechnology, University of Nigeria, Nsukka, Enugu state, Nigeria
| | - John Dike Nwabueze Ogbonna
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Adaeze Linda Onugwu
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Chinazom Precious Agbo
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Adaeze Chidiebere Echezona
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Ezinwanne Nneoma Ezeibe
- Department of Pharmaceutical Microbiology and Biotechnology, University of Nigeria, Nsukka, Enugu state, Nigeria
| | - Samuel Uzondu
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Frankline Chimaobi Kenechukwu
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Paul Achile Akpa
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Mumuni Audu Momoh
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Petra Obioma Nnamani
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Clemence Tarirai
- Department of Pharmaceutical Sciences, Tshwane University of Technology, Pretoria, South Africa
| | - Kenneth Chibuzor Ofokansi
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Anthony Amaechi Attama
- Drug Delivery & Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria
| |
Collapse
|
71
|
Khorenko M, Rand U, Cicin-Sain L, Feldmann C. Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles for Effective Antiviral Therapy. ACS Biomater Sci Eng 2022; 8:1596-1603. [PMID: 35344659 PMCID: PMC9007112 DOI: 10.1021/acsbiomaterials.2c00074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
[ZrO]2+[(FCN)0.4(OH)0.8]2- and Gd3+[FCN]3- inorganic-organic hybrid nanoparticles (IOH-NPs) are novel saline antiviral nanocarriers with foscarnet (FCN) as a drug anion. FCN as a pyrophosphate analogue serves as a prototype of a viral DNA polymerase inhibitor. FCN is used for the treatment of herpesvirus infections, including the drug-resistant cytomegalovirus (CMV) and herpes simplex viruses, HSV-1 and HSV-2. The novel [ZrO]2+[(FCN)0.4(OH)0.8]2- and Gd3+[FCN]3- IOH-NPs are characterized by aqueous synthesis, small size (20-30 nm), low material complexity, high biocompatibility, and high drug load (up to 44 wt % FCN per nanoparticle). The antiviral activity of the FCN-type IOH-NPs is probed for the human cytomegalovirus (HCMV). Moreover, the uptake of FCN-type IOH-NPs into vesicles, cytoplasm, and nuclei of nonphagocytic lung epithelial cells is evaluated. As a result, a promising antiviral activity of the FCN-type IOH-NPs that significantly outperforms freely dissolved FCN at the level of clinical formulations is observed, encouraging a future use of FCN-type IOH-NPs for the delivery of antivirals against respiratory viruses.
Collapse
Affiliation(s)
- Mikhail Khorenko
- Institute of Inorganic Chemistry, Karlsruhe Institute of Technology (KIT), Engesserstrasse 15, D-76131 Karlsruhe, Germany
| | - Ulfert Rand
- Helmholtz Center for Infection Research, Inhoffenstraße 7, D-38124 Braunschweig, Germany
| | - Luka Cicin-Sain
- Helmholtz Center for Infection Research, Inhoffenstraße 7, D-38124 Braunschweig, Germany
| | - Claus Feldmann
- Institute of Inorganic Chemistry, Karlsruhe Institute of Technology (KIT), Engesserstrasse 15, D-76131 Karlsruhe, Germany
| |
Collapse
|
72
|
Sharma M, Bakshi AK, Mittapelly N, Gautam S, Marwaha D, Rai N, Singh N, Tiwari P, Aggarwal N, Kumar A, Mishra PR. Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. J Control Release 2022; 346:43-70. [DOI: 10.1016/j.jconrel.2022.04.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 04/04/2022] [Accepted: 04/05/2022] [Indexed: 02/07/2023]
|
73
|
Funari R, Fukuyama H, Shen AQ. Nanoplasmonic multiplex biosensing for COVID-19 vaccines. Biosens Bioelectron 2022; 208:114193. [PMID: 35421841 PMCID: PMC8968208 DOI: 10.1016/j.bios.2022.114193] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 03/11/2022] [Accepted: 03/14/2022] [Indexed: 12/24/2022]
Abstract
The ongoing emergence of severe acute respiratory syndrome caused by the new coronavirus (SARS-CoV-2) variants requires swift actions in identifying specific antigens and optimizing vaccine development to maximize the humoral response of the patient. Measuring the specificity and the amount of antibody produced by the host immune system with high throughput and accuracy is critical to develop timely diagnostics and therapeutic strategies. Motivated by finding an easy-to-use and cost-effective alternative to existing serological methodologies for multiplex analysis, we develop a proof-of-concept multiplex nanoplasmonic biosensor to capture the humoral response in serums against multiple antigens. Nanoplasmonic sensing relies on the wavelength shift of the localized surface plasmon resonance (LSPR) peak of gold nanostructures upon binding interactions between the antibodies and the immobilized antigens. Here the antigens are first immobilized on different sensing areas by using a mono-biotinylation system based on the high affinity interaction between biotin and streptavidin. We then validate the multiplex platform by detecting the presence of 3 monoclonal antibodies against 3 antigens (2 different hemagglutinins (HAs) from influenza viruses, and the SARS-CoV-2 Spike RBD (receptor binding domain)). We also measure the humoral response in murine sera collected before and after its immunization with the SARS-CoV-2 Spike protein, in good agreement with the results obtained by the ELISA assay. Our nanoplasmonic assays have successfully demonstrated multiple serum antibody profiling, which can be further integrated with microfluidics as an effective high throughput screening platform in future studies for the ongoing SARS-CoV-2 vaccine development.
Collapse
Affiliation(s)
- Riccardo Funari
- Micro/Bio/Nanofluidics Unit, Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna-son, Okinawa, 904-0495, Japan; Dipartimento di Fisica "M. Merlin", Università degli Studi di Bari "Aldo Moro", Bari, 70125, Italy.
| | - Hidehiro Fukuyama
- Laboratory for Lymphocyte Differentiations, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, 230-0045, Japan; Near-InfraRed Photo-Immunotherapy Research Institute, Kansai Medical University, Hirakata, Osaka, 573-1010, Japan; INSERM EST, Strasbourg Cedex 2, 67037, France.
| | - Amy Q Shen
- Micro/Bio/Nanofluidics Unit, Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna-son, Okinawa, 904-0495, Japan.
| |
Collapse
|
74
|
Zhu M, Huangfu C, Wan W, Wang M, Lv H, Zhang X, Wang F, Zhi H, Huang Y, Chen M, Zhao J, Li C, Dong X, Gao Z, Liu Y, Feng L. A Novel Virus Detection Strategy Enabled by TR512-Peptide-Based Bioorthogonal Capture and Enrichment of Preamplified Nucleic Acid. Anal Chem 2022; 94:5591-5598. [PMID: 35348340 DOI: 10.1021/acs.analchem.1c05315] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
High-cost viral nucleic acid detection devices (e.g., qPCR system) are limited resources for developing counties and rural areas, leading to underdiagnosis or even pandemics of viral infectious diseases. Herein, a novel virus detection strategy is reported. Such detection method is enabled by TR512-peptide-based biorthogonal capture and enrichment of commercially available Texas red fluorophore labeled nucleic acid on the functionalized paper. The GST-TR512 fusion protein electrostatically immobilized on the paper is constructed to retain the binding affinity of TR512-peptide toward Texas red fluorophore labeled nucleic acid released in the preamplification process, then the enrichment of analytes enhances fluorescence signal for rapid detection as volume of sample filters through the paper. The method is generally applicable to different nucleic acid preamplification strategies (PCR, RAA, CRISPR) and different virus types (Hepatitis B virus (HBV), African swine fever virus (ASFV), human papillomavirus (HPV), and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 or 2019 nCoV)). Finally, a full-set virus detection device is developed in house to detect the presence of Hepatitis B virus (HBV) viral gene in patients' blood samples. Taken together, we first apply TR512-peptide in the signal enrichment and the novel detection strategy may offer an inexpensive, rapid, and portable solution for areas with limited access to a standard diagnosis laboratory.
Collapse
Affiliation(s)
- Mingzhen Zhu
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China.,University of Chinese Academy of Sciences, Beijing 100049, P. R. China
| | - Changxin Huangfu
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China.,University of Chinese Academy of Sciences, Beijing 100049, P. R. China
| | - Wang Wan
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China
| | - Mengdie Wang
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China.,University of Chinese Academy of Sciences, Beijing 100049, P. R. China
| | - Haochen Lv
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China
| | - Xiaobo Zhang
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China.,University of Chinese Academy of Sciences, Beijing 100049, P. R. China
| | - Fengya Wang
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China.,University of Chinese Academy of Sciences, Beijing 100049, P. R. China
| | - Hui Zhi
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China.,University of Chinese Academy of Sciences, Beijing 100049, P. R. China
| | - Yanan Huang
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China
| | - Meng Chen
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China
| | - Jizhe Zhao
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China
| | - Chunsheng Li
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China
| | - Xuepeng Dong
- The Second Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian 116044, P. R. China
| | - Zhenming Gao
- The Second Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian 116044, P. R. China
| | - Yu Liu
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China
| | - Liang Feng
- Department of Instrumentation and Analytical Chemistry, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, P. R. China
| |
Collapse
|
75
|
Biogenic Synthesis of Antibacterial, Hemocompatible, and Antiplatelets Lysozyme Functionalized Silver Nanoparticles through the One-Step Process for Therapeutic Applications. Processes (Basel) 2022. [DOI: 10.3390/pr10040623] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
To evaluate silver nanoparticles’ (AgNPs) therapeutic and clinical potentials, antibacterial action, blood compatibility, and antiplatelet activities are the main concerns for toxicity profiling. Heat-denatured lysozyme-mediated formulation stabilized the AgNPs, thereby providing more bactericidal activity and blood compatibility. The study of the synthesis of AgNPs suggests the rapid and cost-effective formulation of AgNPs by one-step reaction using a 10:1 ratio of silver nitrate and lysozyme by incubating at 60 °C for two hours. Characterization of AgNPs was analyzed by UV–Visible spectroscopy, DLS, TEM, EDX, XRD, AFM, and FTIR, followed by antibacterial, hemocompatibility, and platelet aggregation testing. The average size of synthesized AgNPs was found to be 94.10 nm with 0.45 mV zeta potential and 0.293 polydispersity index by DLS. The TEM and EXD results indicated homogeneously 28.08 nm spherical-shaped pure formations of AgNPs. The XRD peaks showed the synthesis of small AgNPs with a crystallite size of 22.88 nm, while the AFM confirmed the homogeneity and smoothness of the monodispersed AgNPs. The FTIR spectra specified the coating of the lysozyme-derived amide group on the AgNPs surface, which provides stability and functionality of nanoparticles. The antibacterial activity of AgNPs was remarkable against six pathogenic bacteria and three multidrug resistance (MDR) strains (i.e., Escherichia coli, Klebsiella aerogenes, and Pseudomonas aeruginosa), which exhibited inhibition zones with diameters ranging between 13.5 ± 0.2 mm to 19.0 ± 0.3 mm. The non-hemolytic nature of the AgNPs was calculated by percentage hemolysis with four concentrations. The negative result of platelet aggregation using platelet-rich plasma suggests the antiplatelet effect of AgNPs. Only minor hemolysis of 6.17% in human erythrocytes and mild platelet aggregation of 1.98% were induced, respectively, by the use of 1000 µL of 1 mM AgNPs, which contains approximately 107.8 μg silver. The results indicated that the antiplatelet potency and non-hemolytic nature with the antibacterial action of the lysozyme functionalized AgNPs have a good chance to be used to solve in-stent restenosis and thrombosis issues of the coronary stent and may also have a possibility to use in vaccination to resolve the blood clotting problem. So, the optimized biogenic formulation of AgNPs offers promising opportunities to be used as a therapeutic agent.
Collapse
|
76
|
Lunardi CN, Subrinho FL, Freitas Barros MPD, Lima RC, de Queiroz Melo ACM, Barbosa DDM, Negreiros LGD, Rodrigues BS, Neiva MS, Linhares JVR, Dalla Costa GF, Gomes ADJ. BIBLIOMETRIC ANALYSIS: NANOTECHNOLOGY AND COVID-19. Curr Top Med Chem 2022; 22:629-638. [PMID: 35255795 DOI: 10.2174/1568026622666220307125446] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 01/22/2022] [Accepted: 01/30/2022] [Indexed: 11/22/2022]
Abstract
BACKGROUND COVID-19 pandemic information is critical in order to study it further, but the virus has still not been confined. In addition, even if there is no longer any threat, more knowledge may be gathered from these resources. METHODS The data used in this study was gathered from several scientific areas and the links between them. Due to the fact that the COVID-19 pandemic has not been fully contained and additional information can be gleaned from these references, bibliometric analysis of it is important. RESULTS In total 155 publications on the topic of "COVID-19" and the keyword "nanotechnology" were identified in the Scopus database between 2020 and 2021 in a network visualization map. CONCLUSION As a result, our analysis was conducted at the appropriate time to provide a comprehensive understanding of COVID-19 and nanotechnology and prospective research directions for medicinal chemistry.
Collapse
Affiliation(s)
- Claure Nain Lunardi
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Fernanda Lima Subrinho
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Mirella Paula de Freitas Barros
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Raiane Cavalcante Lima
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Ana Clara Magalhaes de Queiroz Melo
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Daniela de Melo Barbosa
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Luana Gouveia De Negreiros
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Brenda Soares Rodrigues
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Mateus Sousa Neiva
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Joao Victor Ribeiro Linhares
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Gabriel Farrapeira Dalla Costa
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| | - Anderson de Jesus Gomes
- Laboratory of Photochemistry and Nanobiotechnology, University of Brasilia, Campus Universitário Centro Metropolitano 1 Conjunto, Brasília, 72220-900, DF, Brazil
| |
Collapse
|
77
|
Savina K, Sreekumar R, Soonu VK, Variyar EJ. Various vaccine platforms in the field of COVID-19. BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES 2022; 11:35. [PMID: 35284578 PMCID: PMC8899459 DOI: 10.1186/s43088-022-00215-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 02/15/2022] [Indexed: 12/16/2022] Open
Abstract
Background With the emergence of Corona virus Disease-2019, a novel worldwide health disaster is threatening the population. The WHO declared COVID-19 as a pandemic in December 2019, when it first surfaced in Hunan seafood market in Wuhan, South China, and quickly spread far and wide. Different corona virus variants are currently causing concern all across the world. Main body It has become critical for our scientists to develop a viable method to prevent infection or the pandemic from spreading globally. Antiviral medicines, oxygen therapy, and immune system stimulation are all used to treat the condition. SARS-CoV-2 undergoes mutation and due to evolutionary pressures, different mutant strains caused various symptoms in different geographical regions and the epidemic is spreading and becoming more fragile, posing a greater risk of mortality. Vaccines are tools to increase our immunity as a precaution, and increasing the global immunization rate can help improve the situation. Recent developments in the field of vaccine platforms are discussed here. Short conclusion Vaccines are of highest priority to control and eradicate the viral infectious disease COVID-19 more than any other protective solutions. A number of mutations have occurred and some variants such as alpha, beta, gamma, and delta, and it has now progressed to the new version Omicron, which is a variant of concern. Booster doses are anticipated to function as a barrier to the capacity of the most recent known variety, and more research is needed to determine how effective they will be. This page discusses various technologies employed in the field of COVID-19 vaccine, as well as potential barriers and recent developments in this field.
Collapse
|
78
|
Jafari A, Danesh Pouya F, Niknam Z, Abdollahpour-Alitappeh M, Rezaei-Tavirani M, Rasmi Y. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms. Mol Biol Rep 2022; 49:4943-4957. [PMID: 35235159 PMCID: PMC8890022 DOI: 10.1007/s11033-022-07132-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 01/06/2022] [Indexed: 02/06/2023]
Abstract
The world is grappling with an unprecedented public health crisis COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2. Due to the high transmission/mortality rates and socioeconomic impacts of the COVID-19, its control is crucial. In the absence of specific treatment, vaccines represent the most efficient way to control and stop the pandemic. Many companies around the world are currently making efforts to develop the vaccine to combat COVID-19. This review outlines key strategies for generating SARS-CoV-2 vaccine candidates, along with the mechanism of action, advantages, and potential limitations of each vaccine. The use of nanomaterials and nanotechnology for COVID-19 vaccines development will also be discussed.
Collapse
Affiliation(s)
- Ameneh Jafari
- Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.,Proteomics Research Center, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Fahima Danesh Pouya
- Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
| | - Zahra Niknam
- Proteomics Research Center, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Meghdad Abdollahpour-Alitappeh
- Cellular and Molecular Biology Research Center, Larestan University of Medical Sciences, Larestan, Iran.,Student Research Committee, Larestan University of Medical Sciences, Larestan, Iran
| | - Mostafa Rezaei-Tavirani
- Proteomics Research Center, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Yousef Rasmi
- Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.,Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran
| |
Collapse
|
79
|
Aghamirza Moghim Aliabadi H, Eivazzadeh‐Keihan R, Beig Parikhani A, Fattahi Mehraban S, Maleki A, Fereshteh S, Bazaz M, Zolriasatein A, Bozorgnia B, Rahmati S, Saberi F, Yousefi Najafabadi Z, Damough S, Mohseni S, Salehzadeh H, Khakyzadeh V, Madanchi H, Kardar GA, Zarrintaj P, Saeb MR, Mozafari M. COVID-19: A systematic review and update on prevention, diagnosis, and treatment. MedComm (Beijing) 2022; 3:e115. [PMID: 35281790 PMCID: PMC8906461 DOI: 10.1002/mco2.115] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 12/18/2021] [Accepted: 12/19/2021] [Indexed: 01/09/2023] Open
Abstract
Since the rapid onset of the COVID-19 or SARS-CoV-2 pandemic in the world in 2019, extensive studies have been conducted to unveil the behavior and emission pattern of the virus in order to determine the best ways to diagnosis of virus and thereof formulate effective drugs or vaccines to combat the disease. The emergence of novel diagnostic and therapeutic techniques considering the multiplicity of reports from one side and contradictions in assessments from the other side necessitates instantaneous updates on the progress of clinical investigations. There is also growing public anxiety from time to time mutation of COVID-19, as reflected in considerable mortality and transmission, respectively, from delta and Omicron variants. We comprehensively review and summarize different aspects of prevention, diagnosis, and treatment of COVID-19. First, biological characteristics of COVID-19 were explained from diagnosis standpoint. Thereafter, the preclinical animal models of COVID-19 were discussed to frame the symptoms and clinical effects of COVID-19 from patient to patient with treatment strategies and in-silico/computational biology. Finally, the opportunities and challenges of nanoscience/nanotechnology in identification, diagnosis, and treatment of COVID-19 were discussed. This review covers almost all SARS-CoV-2-related topics extensively to deepen the understanding of the latest achievements (last updated on January 11, 2022).
Collapse
Affiliation(s)
- Hooman Aghamirza Moghim Aliabadi
- Protein Chemistry LaboratoryDepartment of Medical BiotechnologyBiotechnology Research CenterPasteur Institute of IranTehranIran
- Advance Chemical Studies LaboratoryFaculty of ChemistryK. N. Toosi UniversityTehranIran
| | | | - Arezoo Beig Parikhani
- Department of Medical BiotechnologyBiotechnology Research CenterPasteur InstituteTehranIran
| | | | - Ali Maleki
- Department of ChemistryIran University of Science and TechnologyTehranIran
| | | | - Masoume Bazaz
- Department of Medical BiotechnologyBiotechnology Research CenterPasteur InstituteTehranIran
| | | | | | - Saman Rahmati
- Department of Medical BiotechnologyBiotechnology Research CenterPasteur InstituteTehranIran
| | - Fatemeh Saberi
- Department of Medical BiotechnologySchool of Advanced Technologies in MedicineShahid Beheshti University of Medical SciencesTehranIran
| | - Zeinab Yousefi Najafabadi
- Department of Medical BiotechnologySchool of Advanced Technologies in MedicineTehran University of Medical SciencesTehranIran
- ImmunologyAsthma & Allergy Research InstituteTehran University of Medical SciencesTehranIran
| | - Shadi Damough
- Department of Medical BiotechnologyBiotechnology Research CenterPasteur InstituteTehranIran
| | - Sara Mohseni
- Non‐metallic Materials Research GroupNiroo Research InstituteTehranIran
| | | | - Vahid Khakyzadeh
- Department of ChemistryK. N. Toosi University of TechnologyTehranIran
| | - Hamid Madanchi
- School of MedicineSemnan University of Medical SciencesSemnanIran
- Drug Design and Bioinformatics UnitDepartment of Medical BiotechnologyBiotechnology Research CenterPasteur Institute of IranTehranIran
| | - Gholam Ali Kardar
- Department of Medical BiotechnologySchool of Advanced Technologies in MedicineTehran University of Medical SciencesTehranIran
- ImmunologyAsthma & Allergy Research InstituteTehran University of Medical SciencesTehranIran
| | - Payam Zarrintaj
- School of Chemical EngineeringOklahoma State UniversityStillwaterOklahomaUSA
| | - Mohammad Reza Saeb
- Department of Polymer TechnologyFaculty of ChemistryGdańsk University of TechnologyGdańskPoland
| | - Masoud Mozafari
- Department of Tissue Engineering & Regenerative MedicineIran University of Medical SciencesTehranIran
| |
Collapse
|
80
|
Dubey AK, Chaudhry SK, Singh HB, Gupta VK, Kaushik A. Perspectives on nano-nutraceuticals to manage pre and post COVID-19 infections. BIOTECHNOLOGY REPORTS (AMSTERDAM, NETHERLANDS) 2022; 33:e00712. [PMID: 35186674 PMCID: PMC8832856 DOI: 10.1016/j.btre.2022.e00712] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Accepted: 02/10/2022] [Indexed: 12/12/2022]
Abstract
Optimized therapeutic bio-compounds supported by bio-acceptable nanosystems (i.e., precise nanomedicine) have ability to promote health via maintaining body structure, organ function, and controlling chronic and acute effects. Therefore, nano-nutraceuticals (designed to neutralize virus, inhibit virus bindings with receptors, and support immunity) utilization can manage COVID-19 pre/post-infection effects. To explore these approaches well, our mini-review explores optimized bio-active compounds, their ability to influence SARS-CoV-2 infection, improvement in performance supported by precise nanomedicine approach, and challenges along with prospects. Such optimized pharmacologically relevant therapeutic cargo not only affect SARS-CoV-2 but will support other organs which show functional alternation due to SARS-CoV-2 for example, neurological functions. Hence, coupling the nutraceuticals with the nano-pharmacology perspective of higher efficacy via targeted delivery action can pave a novel way for health experts to plan future research needed to manage post COVID-19 infection effect where a longer efficacy with no side-effects is a key requirement.
Collapse
Affiliation(s)
- Ankit Kumar Dubey
- Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Tamil Nadu, 600036, India
- Institute of Scholars (InSc), Bengaluru, 560091, Karnataka, India
| | - Suman Kumar Chaudhry
- Department of Computer Science and Engineering, Tezpur University, Sonitpur, Assam, 784028, India
| | | | - Vijai Kumar Gupta
- Biorefining and Advanced Materials Research Center, SRUC, Kings Buildings, West Mains Road, Edinburgh EH9 3JG, United Kingdom
- Center for Safe and Improved Food, SRUC, Kings Buildings, West Mains Road, Edinburgh EH9 3JG, United Kingdom
| | - Ajeet Kaushik
- NanoBioTech Laboratory, Health Systems Engineering, Department of Natural Sciences, Florida Polytechnic University, Lakeland, FL, 33805, United States of America
| |
Collapse
|
81
|
Souri M, Chiani M, Farhangi A, Mehrabi MR, Nourouzian D, Raahemifar K, Soltani M. Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment. NANOMATERIALS (BASEL, SWITZERLAND) 2022; 12:783. [PMID: 35269270 PMCID: PMC8912597 DOI: 10.3390/nano12050783] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 02/18/2022] [Accepted: 02/23/2022] [Indexed: 02/04/2023]
Abstract
Following the announcement of the outbreak of COVID-19 by the World Health Organization, unprecedented efforts were made by researchers around the world to combat the disease. So far, various methods have been developed to combat this "virus" nano enemy, in close collaboration with the clinical and scientific communities. Nanotechnology based on modifiable engineering materials and useful physicochemical properties has demonstrated several methods in the fight against SARS-CoV-2. Here, based on what has been clarified so far from the life cycle of SARS-CoV-2, through an interdisciplinary perspective based on computational science, engineering, pharmacology, medicine, biology, and virology, the role of nano-tools in the trio of prevention, diagnosis, and treatment is highlighted. The special properties of different nanomaterials have led to their widespread use in the development of personal protective equipment, anti-viral nano-coats, and disinfectants in the fight against SARS-CoV-2 out-body. The development of nano-based vaccines acts as a strong shield in-body. In addition, fast detection with high efficiency of SARS-CoV-2 by nanomaterial-based point-of-care devices is another nanotechnology capability. Finally, nanotechnology can play an effective role as an agents carrier, such as agents for blocking angiotensin-converting enzyme 2 (ACE2) receptors, gene editing agents, and therapeutic agents. As a general conclusion, it can be said that nanoparticles can be widely used in disinfection applications outside in vivo. However, in in vivo applications, although it has provided promising results, it still needs to be evaluated for possible unintended immunotoxicity. Reviews like these can be important documents for future unwanted pandemics.
Collapse
Affiliation(s)
- Mohammad Souri
- Department of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran; (M.S.); (M.C.); (A.F.)
- Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran 19967-15433, Iran
| | - Mohsen Chiani
- Department of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran; (M.S.); (M.C.); (A.F.)
| | - Ali Farhangi
- Department of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran; (M.S.); (M.C.); (A.F.)
| | - Mohammad Reza Mehrabi
- Department of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran; (M.S.); (M.C.); (A.F.)
| | - Dariush Nourouzian
- Department of NanoBiotechnology, Pasteur Institute of Iran, Tehran 13169-43551, Iran; (M.S.); (M.C.); (A.F.)
| | - Kaamran Raahemifar
- Data Science and Artificial Intelligence Program, College of Information Sciences and Technology (IST), Penn State University, State College, PA 16801, USA;
- Department of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada
- School of Optometry and Vision Science, Faculty of Science, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada
| | - M. Soltani
- Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran 19967-15433, Iran
- Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada
- Centre for Biotechnology and Bioengineering (CBB), University of Waterloo, Waterloo, ON N2L 3G1, Canada
- Advanced Bioengineering Initiative Center, Multidisciplinary International Complex, K. N. Toosi University of Technology, Tehran 14176-14411, Iran
| |
Collapse
|
82
|
Wang J, Yin XG, Wen Y, Lu J, Zhang RY, Zhou SH, Liao CM, Wei HW, Guo J. MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern. J Med Chem 2022; 65:3563-3574. [PMID: 35108485 PMCID: PMC8848510 DOI: 10.1021/acs.jmedchem.1c02025] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Indexed: 12/31/2022]
Abstract
Safe and effective vaccines are the best method to defeat worldwide SARS-CoV-2 and its circulating variants. The SARS-CoV-2 S protein and its subunits are the most attractive targets for the development of protein-based vaccines. In this study, we evaluated three lipophilic adjuvants, monophosphoryl lipid A (MPLA), Toll-like receptor (TLR) 1/2 ligand Pam3CSK4, and α-galactosylceramide (α-GalCer), in liposomal and nonliposomal vaccines. The immunological results showed that the MPLA-adjuvanted liposomal vaccine induced the strongest humoral and cellular immunity. Therefore, we further performed a systematic comparison of S-trimer, S-ECD, S1, and RBD as antigens in MPLA-adjuvanted liposomes and found that, although these four vaccines all induced robust specific antibody responses, only S-trimer, S1, and RBD liposomes, but not S-ECD, elicited potent neutralizing antibody responses. Moreover, RBD, S-trimer, and S1 liposomes effectively neutralized variants (B.1.1.7/alpha, B.1.351/beta, P.1/gamma, B.1.617.2/delta, and B.1.1.529/omicron). These results provide important information for the subunit vaccine design against SARS-CoV-2 and its variants.
Collapse
Affiliation(s)
- Jian Wang
- Key Laboratory of Pesticide and Chemical Biology of
Ministry of Education, International Joint Research Center for Intelligent Biosensing
Technology and Health, Hubei International Scientific and Technological Cooperation Base
of Pesticide and Green Synthesis, College of Chemistry, Central China Normal
University, Wuhan 430079, China
| | - Xu-Guang Yin
- School of Medical Sciences, Shaoxing
University, Zhejiang 312000, China
| | - Yu Wen
- Key Laboratory of Pesticide and Chemical Biology of
Ministry of Education, International Joint Research Center for Intelligent Biosensing
Technology and Health, Hubei International Scientific and Technological Cooperation Base
of Pesticide and Green Synthesis, College of Chemistry, Central China Normal
University, Wuhan 430079, China
| | - Jie Lu
- Key Laboratory of Pesticide and Chemical Biology of
Ministry of Education, International Joint Research Center for Intelligent Biosensing
Technology and Health, Hubei International Scientific and Technological Cooperation Base
of Pesticide and Green Synthesis, College of Chemistry, Central China Normal
University, Wuhan 430079, China
| | - Ru-Yan Zhang
- Key Laboratory of Pesticide and Chemical Biology of
Ministry of Education, International Joint Research Center for Intelligent Biosensing
Technology and Health, Hubei International Scientific and Technological Cooperation Base
of Pesticide and Green Synthesis, College of Chemistry, Central China Normal
University, Wuhan 430079, China
| | - Shi-Hao Zhou
- Key Laboratory of Pesticide and Chemical Biology of
Ministry of Education, International Joint Research Center for Intelligent Biosensing
Technology and Health, Hubei International Scientific and Technological Cooperation Base
of Pesticide and Green Synthesis, College of Chemistry, Central China Normal
University, Wuhan 430079, China
| | - Chun-Miao Liao
- Key Laboratory of Pesticide and Chemical Biology of
Ministry of Education, International Joint Research Center for Intelligent Biosensing
Technology and Health, Hubei International Scientific and Technological Cooperation Base
of Pesticide and Green Synthesis, College of Chemistry, Central China Normal
University, Wuhan 430079, China
| | - Hua-Wei Wei
- Jiangsu East-Mab Biomedical Technology Co.
Ltd, Nantong 226499, China
| | - Jun Guo
- Key Laboratory of Pesticide and Chemical Biology of
Ministry of Education, International Joint Research Center for Intelligent Biosensing
Technology and Health, Hubei International Scientific and Technological Cooperation Base
of Pesticide and Green Synthesis, College of Chemistry, Central China Normal
University, Wuhan 430079, China
| |
Collapse
|
83
|
Abstract
This review discusses peptide epitopes used as antigens in the development of vaccines in clinical trials as well as future vaccine candidates. It covers peptides used in potential immunotherapies for infectious diseases including SARS-CoV-2, influenza, hepatitis B and C, HIV, malaria, and others. In addition, peptides for cancer vaccines that target examples of overexpressed proteins are summarized, including human epidermal growth factor receptor 2 (HER-2), mucin 1 (MUC1), folate receptor, and others. The uses of peptides to target cancers caused by infective agents, for example, cervical cancer caused by human papilloma virus (HPV), are also discussed. This review also provides an overview of model peptide epitopes used to stimulate non-specific immune responses, and of self-adjuvanting peptides, as well as the influence of other adjuvants on peptide formulations. As highlighted in this review, several peptide immunotherapies are in advanced clinical trials as vaccines, and there is great potential for future therapies due the specificity of the response that can be achieved using peptide epitopes.
Collapse
Affiliation(s)
- Ian W Hamley
- Department of Chemistry, University of Reading, Whiteknights, Reading RG6 6AD, U.K
| |
Collapse
|
84
|
Abstract
A favorable outcome of the COVID-19 crisis might be achieved with massive vaccination. The proposed vaccines contain several different vaccine active principles (VAP), such as inactivated virus, antigen, mRNA, and DNA, which are associated with either standard adjuvants or nanomaterials (NM) such as liposomes in Moderna's and BioNTech/Pfizer's vaccines. COVID-19 vaccine adjuvants may be chosen among liposomes or other types of NM composed for example of graphene oxide, carbon nanotubes, micelles, exosomes, membrane vesicles, polymers, or metallic NM, taking inspiration from cancer nano-vaccines, whose adjuvants may share some of their properties with those of viral vaccines. The mechanisms of action of nano-adjuvants are based on the facilitation by NM of targeting certain regions of immune interest such as the mucus, lymph nodes, and zones of infection or blood irrigation, the possible modulation of the type of attachment of the VAP to NM, in particular VAP positioning on the NM external surface to favor VAP presentation to antigen presenting cells (APC) or VAP encapsulation within NM to prevent VAP degradation, and the possibility to adjust the nature of the immune response by tuning the physico-chemical properties of NM such as their size, surface charge, or composition. The use of NM as adjuvants or the presence of nano-dimensions in COVID-19 vaccines does not only have the potential to improve the vaccine benefit/risk ratio, but also to reduce the dose of vaccine necessary to reach full efficacy. It could therefore ease the overall spread of COVID-19 vaccines within a sufficiently large portion of the world population to exit the current crisis.
Collapse
Affiliation(s)
- Edouard Alphandéry
- Sorbonne Université, Muséum National d'Histoire Naturelle, UMR CNRS 7590, IRD, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, 75005 Paris, France. .,Nanobacterie SARL, 36 Boulevard Flandrin, 75116, Paris, France.,Institute of Anatomy, UZH University of Zurich, Instiute of Anatomy, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland
| |
Collapse
|
85
|
Zeng N, Chen X, Liu Z. Natural Products and Nanotechnology Against Coronavirus Disease 2019. Front Chem 2022; 10:819969. [PMID: 35223771 PMCID: PMC8866311 DOI: 10.3389/fchem.2022.819969] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Accepted: 01/21/2022] [Indexed: 12/22/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) is a new and severe infectious disease and new global disaster and is spreading rapidly worldwide. Natural products have a long history and have been widely used to treat various acute, chronic, and even life-threatening diseases worldwide. However, the natural products have reduced bioavailability and availability as they have poor kinetic properties, such as large molecular weight, inability to cross lipid membranes, and weak absorption ability. With the rapid development of nanotechnology, using novel nanotechnology in conjunction with natural products can effectively eliminate the molecular restriction of the entry of nanoproducts into the body and can be used to diagnose and treat various diseases, including COVID-19, bringing new strategies and directions for medicine. This article reviews the role and implementation of natural products against COVID-19 based on nanotechnology.
Collapse
|
86
|
Morgulchik N, Athanasopoulou F, Chu E, Lam Y, Kamaly N. Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm. Interface Focus 2022; 12:20210006. [PMID: 34956607 PMCID: PMC8662389 DOI: 10.1098/rsfs.2021.0006] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Accepted: 10/14/2021] [Indexed: 12/15/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) is a deadly respiratory disease caused by severe acute respiratory syndrome coronavirus 2, which has caused a global pandemic since early 2020 and severely threatened people's livelihoods and health. Patients with pre-diagnosed conditions admitted to hospital often develop complications leading to mortality due to acute respiratory distress syndrome (ARDS) and associated multiorgan failure and blood clots. ARDS is associated with a cytokine storm. Cytokine storms arise due to elevated levels of circulating cytokines and are associated with infections. Targeting various pro-inflammatory cytokines in a specific manner can result in a potent therapeutic approach with minimal host collateral damage. Immunoregulatory therapies are now of interest in order to regulate the cytokine storm, and this review will summarize and discuss advances in targeted therapies against cytokine storms induced by COVID-19.
Collapse
Affiliation(s)
- Nelli Morgulchik
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, UK
| | - Foteini Athanasopoulou
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, UK
| | - Edmund Chu
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, UK
| | - Yoriko Lam
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, UK
| | - Nazila Kamaly
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, UK
| |
Collapse
|
87
|
Grinin L, Grinin A, Korotayev A. COVID-19 pandemic as a trigger for the acceleration of the cybernetic revolution, transition from e-government to e-state, and change in social relations. TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE 2022; 175:121348. [PMID: 34789950 PMCID: PMC8585613 DOI: 10.1016/j.techfore.2021.121348] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 11/04/2021] [Accepted: 11/07/2021] [Indexed: 05/27/2023]
Abstract
Among many influences that the pandemic has and will have on society and the World System as a whole, one of the most important is the acceleration of the start of a new technological wave and a new technological paradigm in the near future. This impact is determined by the growing need for the development of a number of areas in medicine, bio- and nanotechnology, artificial intelligence and others, which we denote as "MANBRIC convergence". It is shown that the experience of dealing with the COVID-19 pandemic has confirmed that the final phase of the Cybernetic Revolution will begin in the 2030s at the intersection of a number of medical, bio, digital and several other technologies, with medical needs as an integrating link. Among the multitude of self-regulating systems in the economy and life (which, in our opinion, will flourish during the Cybernetic Revolution) socio-technical self-regulating systems (SSSs) will play a special role. Thus, COVID-19 becomes a powerful impetus not only in terms of accelerating technological development and approaching the final phase of the Cybernetic Revolution, but also in changing sociopolitical (and socio-administrative) relations in the forthcoming decades.
Collapse
Affiliation(s)
- Leonid Grinin
- HSE University, Moscow; Institute of Oriental Studies, Russian Academy of Sciences,Russia
| | | | - Andrey Korotayev
- HSE University, Moscow; Institute of Oriental Studies, Russian Academy of Sciences, Russia
| |
Collapse
|
88
|
Costoya J, Surnar B, Kalathil AA, Kolishetti N, Dhar S. Controlled release nanoplatforms for three commonly used chemotherapeutics. Mol Aspects Med 2022; 83:101043. [PMID: 34920863 PMCID: PMC10074549 DOI: 10.1016/j.mam.2021.101043] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 09/28/2021] [Accepted: 09/29/2021] [Indexed: 12/11/2022]
Abstract
In order to combat an evolving, multidimensional disease such as cancer, research has been aimed at synthesizing more efficient and effective versions of popular chemotherapeutic drugs. Despite these efforts, there remains a necessity for the development of suitable delivery vehicles that can both harness the chemotherapeutic effects meanwhile reducing some of the known issues when using these drugs such as unwanted side-effects, acquired drug resistance, and associated difficulties with drug delivery. Synthetic drug discovery approaches focusing on modification of the native structure of these chemotherapeutic drugs often face challenges such as loss of efficacy, as well as a potential worsening of side-effects. Synthetic chemists are then left with increasingly narrow choices for possible chemistry they could implement to achieve the desired therapy. The emergence of targeted therapies using controlled-release nanomaterials can provide many opportunities for conventional chemotherapeutic drugs to be delivered to specific target sites, ultimately leading to reduced side-effects and improved efficacy. Logically, it may prove advantageous to consider nano-delivery systems as a likely candidate for circumventing some of the barriers associated with creating viable drug therapies. In this review, we summarize controlled release nanoformulations of the three most widely used and approved chemotherapeutics, doxorubicin, paclitaxel, and cisplatin as an alternative therapeutic approach against different cancer types.
Collapse
Affiliation(s)
- Joel Costoya
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA
| | - Bapurao Surnar
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA
| | - Akil A Kalathil
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA
| | - Nagesh Kolishetti
- Department of Immunology and Nano-Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, 33199, USA
| | - Shanta Dhar
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
| |
Collapse
|
89
|
Chen Y, Huang Y, Jin Q. Polymeric nanoplatforms for the delivery of antibacterial agents. MACROMOL CHEM PHYS 2022. [DOI: 10.1002/macp.202100440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Yongcheng Chen
- MOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education Department of Polymer Science and Engineering Zhejiang University Hangzhou Zhejiang 310027 PR China
| | - Yue Huang
- MOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education Department of Polymer Science and Engineering Zhejiang University Hangzhou Zhejiang 310027 PR China
| | - Qiao Jin
- MOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education Department of Polymer Science and Engineering Zhejiang University Hangzhou Zhejiang 310027 PR China
| |
Collapse
|
90
|
Wang C, Meng N, Babar AA, Gong X, Liu G, Wang X, Yu J, Ding B. Highly Transparent Nanofibrous Membranes Used as Transparent Masks for Efficient PM 0.3 Removal. ACS NANO 2022; 16:119-128. [PMID: 34870426 DOI: 10.1021/acsnano.1c09055] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Currently, the quest for highly transparent and flexible fibrous membranes with robust mechanical characteristics, high breathability, and good filtration performance is rapidly rising because of their potential use in the fields of electronics, energy, environment, medical, and health. However, it is still an extremely challenging task to realize transparent fibrous membranes due to serious surface light reflection and internal light scattering. Here, we report the design and development of a simple and effective topological structure to create porous, breathable, and high visible light transmitting fibrous membranes (HLTFMs). The resultant HLTFMs exhibit good optical performance (up to 90% transmittance) and high porosities (>80%). The formation of such useful structure with high light transmittance has been revealed by electric field simulation, and the mechanism of fibrous membrane structure to achieve high light transmittance has been proposed. Moreover, transparent masks have been prepared to evaluate the filtration performance and analyze their feasibility to meet requirement of facial recognition systems. The prepared masks display high transparency (>80%), low pressure drop (<100 Pa) and high filtration efficiency (>90%). Furthermore, the person wearing this mask can be successfully identified by facial recognition systems. Therefore, this work provides an idea for the development of transparent, breathable, and high-performance fibrous membranes.
Collapse
Affiliation(s)
- Chao Wang
- Innovation Center for Textile Science and Technology, College of Textiles, Donghua University, Shanghai 200051, China
| | - Na Meng
- Innovation Center for Textile Science and Technology, College of Textiles, Donghua University, Shanghai 200051, China
| | - Aijaz Ahmed Babar
- Innovation Center for Textile Science and Technology, College of Textiles, Donghua University, Shanghai 200051, China
| | - Xiaobao Gong
- Innovation Center for Textile Science and Technology, College of Textiles, Donghua University, Shanghai 200051, China
| | - Gaohui Liu
- Innovation Center for Textile Science and Technology, College of Textiles, Donghua University, Shanghai 200051, China
| | - Xianfeng Wang
- Innovation Center for Textile Science and Technology, College of Textiles, Donghua University, Shanghai 200051, China
| | - Jianyong Yu
- Innovation Center for Textile Science and Technology, College of Textiles, Donghua University, Shanghai 200051, China
| | - Bin Ding
- Innovation Center for Textile Science and Technology, College of Textiles, Donghua University, Shanghai 200051, China
| |
Collapse
|
91
|
Debnath SK, Srivastava R. Potential Application of Bionanoparticles to Treat Severe Acute Respiratory Syndrome Coronavirus-2 Infection. FRONTIERS IN NANOTECHNOLOGY 2022. [DOI: 10.3389/fnano.2021.813847] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a contagious virus that spreads exponentially across the world, resulting in serious viral pneumonia. Several companies and researchers have put their tremendous effort into developing novel vaccines or drugs for the complete eradication of COVID-19 caused by SARS-CoV-2. Bionanotechnology plays a vital role in designing functionalized biocompatible nanoparticulate systems with higher antiviral capabilities. Thus, several nanocarriers have been explored in designing and delivering drugs and vaccines. This problem can be overcome with the intervention of biomaterials or bionanoparticles. The present review describes the comparative analysis of SARS infection and its associated etiological agents. This review also highlighted some nanoparticles that have been explored in the treatment of COVID-19. However, these carriers elicit several problems once they come in contact with biological systems. Often, the body’s immune system treats these nanocarriers as foreign particles and antigens. In contrast, some bionanoparticles are highlighted here with their potential application in SARS-CoV-2. However, bionanoparticles have demonstrated some drawbacks discussed here with the possible outcomes. The scope of bioinspired nanoparticles is also discussed in detail to explore the new era of research. It is highly essential for the effective delivery of these nanoparticles to the target site. For effective management of SARS-CoV-2, different delivery patterns are also discussed here.
Collapse
|
92
|
Gupta T, Debele TA, Wei YF, Gupta A, Murtaza M, Su WP. Synergistic Action of Immunotherapy and Nanotherapy against Cancer Patients Infected with SARS-CoV-2 and the Use of Artificial Intelligence. Cancers (Basel) 2022; 14:213. [PMID: 35008377 PMCID: PMC8750412 DOI: 10.3390/cancers14010213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Revised: 12/28/2021] [Accepted: 12/30/2021] [Indexed: 01/08/2023] Open
Abstract
Since 2019, the SARS-CoV-2 pandemic has caused a huge chaos throughout the world and the major threat has been possessed by the immune-compromised individuals involving the cancer patients; their weakened immune response makes them vulnerable and susceptible to the virus. The oncologists as well as their patients are facing many problems for their treatment sessions as they need to postpone their surgery, chemotherapy, or radiotherapy. The approach that could be adopted especially for the cancer patients is the amalgamation of immunotherapy and nanotherapy which can reduce the burden on the healthcare at this peak time of the infection. There is also a need to predict or analyze the data of cancer patients who are at a severe risk of being exposed to an infection in order to reduce the mortality rate. The use of artificial intelligence (AI) could be incorporated where the real time data will be available to the physicians according to the different patient's clinical characteristics and their past treatments. With this data, it will become easier for them to modify or replace the treatment to increase the efficacy against the infection. The combination of an immunotherapy and nanotherapy will be targeted to treat the cancer patients diagnosed with SARS-CoV-2 and the AI will act as icing on the cake to monitor, predict and analyze the data of the patients to improve the treatment regime for the most vulnerable patients.
Collapse
Affiliation(s)
- Tanvi Gupta
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan;
| | - Tilahun Ayane Debele
- Department of Biomedical, Chemical & Environmental Engineering, College of Engineering and Applied Science (CEAS), University of Cincinnati, Cincinnati, OH 45221, USA;
| | - Yu-Feng Wei
- Department of Internal Medicine, School of Medicine for International Students, College of Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung 824, Taiwan;
| | - Anish Gupta
- Devscope IT, First Floor, 40A/B Gandhi Nagar, Jammu 180001, India;
| | - Mohd Murtaza
- Microbial Biotechnology Division, CSIR-Indian Institute of Integrative Medicine, Jammu 180012, India;
| | - Wen-Pin Su
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan;
- Departments of Oncology and Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan
- Center of Applied Nanomedicine, National Cheng Kung University, Tainan 704, Taiwan
| |
Collapse
|
93
|
Gu N, Sheng J. Introduction to Nanomedicine. Nanomedicine (Lond) 2022. [DOI: 10.1007/978-981-13-9374-7_1-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
94
|
Tavares JL, Cavalcanti IDL, Santos Magalhães NS, Lira Nogueira MCDB. Nanotechnology and COVID-19: quo vadis?. JOURNAL OF NANOPARTICLE RESEARCH : AN INTERDISCIPLINARY FORUM FOR NANOSCALE SCIENCE AND TECHNOLOGY 2022; 24:62. [PMID: 35283662 PMCID: PMC8901091 DOI: 10.1007/s11051-022-05452-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Accepted: 03/01/2022] [Indexed: 05/02/2023]
Abstract
The pandemic COVID-19 has worried everyone due to the high mortality rate and the high number of people hospitalized with severe acute respiratory syndrome caused by SARS-CoV-2. Given the seriousness of this disease, several companies and research institutions have sought alternative treatment and/or prevention methods for COVID-19. Due to its versatility, nanotechnology has allowed the development of protective equipment and vaccines to prevent the disease and reduce the number of severe COVID-19 cases. Thus, this article combined the main works and products developed in a nanotechnological field for COVID-19. We performed a literature search using the keywords "COVID-19," "SARS-CoV-2," "nanoparticles," "nanotechnology," and "liposomes" in the SciELO, Scifinder, PubMed, Sciencedirect, ClinicalTrials, and Nanotechnology Products databases Database. The data survey indicated 48 articles, 62 products, and 32 patents. The use of nanotechnology against COVID-19 has brought benefits in several parameters of this disease, helping develop rapid diagnostic tests that release the result in 10 min, as well as developing vaccines containing genetic material from SARS-CoV-2 (DNA, mRNA, and protein subunits). Nanotechnology is an exceptional ally against COVID-19, contributing to the most diverse areas, helping both prevent, diagnose, and treat COVID-19.
Collapse
Affiliation(s)
- João Lima Tavares
- Laboratório de Imunopatologia Keizo-Asami (LIKA), Universidade Federal de Pernambuco (UFPE), Av. Prof. Moraes Rego, Cidade Universitária, Recife, PE 123550670-901 Brazil
- Laboratório de Nanotecnologia, Biotecnologia e Cultura de Células, Centro Acadêmico de Vitória, Universidade Federal de Pernambuco (CAV/UFPE), Recife, Brazil
| | - Iago Dillion Lima Cavalcanti
- Laboratório de Imunopatologia Keizo-Asami (LIKA), Universidade Federal de Pernambuco (UFPE), Av. Prof. Moraes Rego, Cidade Universitária, Recife, PE 123550670-901 Brazil
- Laboratório de Nanotecnologia, Biotecnologia e Cultura de Células, Centro Acadêmico de Vitória, Universidade Federal de Pernambuco (CAV/UFPE), Recife, Brazil
| | - Nereide Stela Santos Magalhães
- Laboratório de Imunopatologia Keizo-Asami (LIKA), Universidade Federal de Pernambuco (UFPE), Av. Prof. Moraes Rego, Cidade Universitária, Recife, PE 123550670-901 Brazil
| | - Mariane Cajubá de Britto Lira Nogueira
- Laboratório de Imunopatologia Keizo-Asami (LIKA), Universidade Federal de Pernambuco (UFPE), Av. Prof. Moraes Rego, Cidade Universitária, Recife, PE 123550670-901 Brazil
- Laboratório de Nanotecnologia, Biotecnologia e Cultura de Células, Centro Acadêmico de Vitória, Universidade Federal de Pernambuco (CAV/UFPE), Recife, Brazil
| |
Collapse
|
95
|
Tiwari AK, Mishra A, Pandey G, Gupta MK, Pandey PC. Nanotechnology: A Potential Weapon to Fight against COVID-19. PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION : MEASUREMENT AND DESCRIPTION OF PARTICLE PROPERTIES AND BEHAVIOR IN POWDERS AND OTHER DISPERSE SYSTEMS 2022; 39:2100159. [PMID: 35440846 PMCID: PMC9011707 DOI: 10.1002/ppsc.202100159] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 08/28/2021] [Indexed: 05/13/2023]
Abstract
The COVID-19 infections have posed an unprecedented global health emergency, with nearly three million deaths to date, and have caused substantial economic loss globally. Hence, an urgent exploration of effective and safe diagnostic/therapeutic approaches for minimizing the threat of this highly pathogenic coronavirus infection is needed. As an alternative to conventional diagnosis and antiviral agents, nanomaterials have a great potential to cope with the current or even future health emergency situation with a wide range of applications. Fundamentally, nanomaterials are physically and chemically tunable and can be employed for the next generation nanomaterial-based detection of viral antigens and host antibodies in body fluids as antiviral agents, nanovaccine, suppressant of cytokine storm, nanocarrier for efficient delivery of antiviral drugs at infection site or inside the host cells, and can also be a significant tool for better understanding of the gut microbiome and SARS-CoV-2 interaction. The applicability of nanomaterial-based therapeutic options to cope with the current and possible future pandemic is discussed here.
Collapse
Affiliation(s)
- Atul K. Tiwari
- Department of ChemistryIndian Institute of Technology (BHU)VaranasiUttar Pradesh221005India
| | - Anupa Mishra
- Department of MicrobiologyDr. R.M.L. Awadh UniversityAyodhyaUttar Pradesh224001India
- Department of MicrobiologySri Raghukul Mahila Vidya PeethCivil Line GondaUttar Pradesh271001India
| | - Govind Pandey
- Department of PaediatricsKing George Medical UniversityLucknowUttar Pradesh226003India
| | - Munesh K. Gupta
- Department of MicrobiologyInstitute of Medical SciencesBanaras Hindu UniversityVaranasiUttar Pradesh221005India
| | - Prem C. Pandey
- Department of ChemistryIndian Institute of Technology (BHU)VaranasiUttar Pradesh221005India
| |
Collapse
|
96
|
Abstract
Unique pneumonia due to an unknown source emerged in December 2019 in the city of Wuhan, China. Consequently, the World Health Organization (WHO) declared this condition as a new coronavirus disease-19 also known as COVID-19 on February 11, 2020, which on March 13, 2020 was declared as a pandemic. The virus that causes COVID-19 was found to have a similar genome (80% similarity) with the previously known acute respiratory syndrome also known as SARS-CoV. The novel virus was later named Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 falls in the family of Coronaviridae which is further divided into Nidovirales and another subfamily called Orthocoronavirinae. The four generations of the coronaviruses belongs to the Orthocoronavirinae family that consists of alpha, beta, gamma and delta coronavirus which are denoted as α-CoV, β-CoV, γ-CoV, δ-CoV respectively. The α-CoV and β-CoVs are mainly known to infect mammals whereas γ-CoV and δ-CoV are generally found in birds. The β-CoVs also comprise of SARS-CoV and also include another virus that was found in the Middle East called the Middle East respiratory syndrome virus (MERS-CoV) and the cause of current pandemic SARS-CoV-2. These viruses initially cause the development of pneumonia in the patients and further development of a severe case of acute respiratory distress syndrome (ARDS) and other related symptoms that can be fatal leading to death.
Collapse
|
97
|
Charelli LE, de Mattos GC, de Jesus Sousa-Batista A, Pinto JC, Balbino TA. Polymeric nanoparticles as therapeutic agents against coronavirus disease. JOURNAL OF NANOPARTICLE RESEARCH : AN INTERDISCIPLINARY FORUM FOR NANOSCALE SCIENCE AND TECHNOLOGY 2022; 24:12. [PMID: 35035277 PMCID: PMC8747451 DOI: 10.1007/s11051-022-05396-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Accepted: 12/30/2021] [Indexed: 05/04/2023]
Abstract
Nanotechnology has the potential to improve the combat against life-threatening conditions. Considering the COVID-19 scenario, and future outbreaks, nanotechnology can play a pivotal role in several steps, ranging from disinfection protocols, manufacture of hospital clothes, to implementation of healthcare settings. Polymeric nanoparticles are colloidal particles with size ranging from 10 to 999 nm, composed of natural or synthetic polymers. The versatility of polymeric-based nanoparticle engineering can provide (i) specificity, (ii) tunable release kinetics, and (iii) multimodal drug composition, making it possible to overcome common limitations encountered during traditional drug development. Consequently, these particles have been widely used as drug delivery systems against several diseases, such as cancer. Due to inherent competitive advantages, polymeric-based nanoparticles hold astonishing potential to counteract the new coronavirus disease (COVID-19). For this reason, in the present study, the latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2 are compiled and discussed. Moreover, the importance of forefront in vitro technologies - such as 3D bioprinting and organ-on-chip - to evaluate the efficacy of nanotherapeutic agents is also highlighted. Polymeric nanoparticles can be functionalized to enhance its potential as a nanotherapeutic agent. Due to its many advantages, polymeric-based nanoparticles systems are a promising approach against coronavirus disease 2019 (COVID-19).
Collapse
Affiliation(s)
- Letícia Emiliano Charelli
- Nanotechnology Engineering Department, Alberto Luiz Coimbra Institute for Graduate Studies and Research in Engineering, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Gabriela Calidone de Mattos
- Chemical Engineering Department, Alberto Luiz Coimbra Institute for Graduate Studies and Research in Engineering, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Ariane de Jesus Sousa-Batista
- Nanotechnology Engineering Department, Alberto Luiz Coimbra Institute for Graduate Studies and Research in Engineering, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - José Carlos Pinto
- Chemical Engineering Department, Alberto Luiz Coimbra Institute for Graduate Studies and Research in Engineering, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Tiago Albertini Balbino
- Nanotechnology Engineering Department, Alberto Luiz Coimbra Institute for Graduate Studies and Research in Engineering, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| |
Collapse
|
98
|
Mall A, Das TR, Bhattacharjee P, Pal S, Sharma S, Shukla SK, Patra S. Role of nanotechnology for coronavirus detection. SENSING TOOLS AND TECHNIQUES FOR COVID-19 2022. [PMCID: PMC9335014 DOI: 10.1016/b978-0-323-90280-9.00005-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
The Coronavirus disease 2019 (COVID-19) is the worst pandemic faced by the mankind in current millennium. It is due to the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This was detected for the first time in December 2019 with rapid human-to-human transmission. The global pandemic has spread out across 213 countries by affecting millions including 52.7 lakh death. Currently, there are no clinically proven therapeutic methods that clearly inhibit the effects of this virus. Nanoparticles (NPs) have been widely used in many medical applications, such as biosensing, drug delivery, imaging, and antimicrobial treatment. Looking the rapid, cost effective and accurate sensing of the virus, the field of nanoscience and nanotechnology is working actively. By following the colorimetric method and surface plasmon spectroscopy, several nanoparticles are used in quantifying and detecting the COVID-19. This chapter contains the rapid analysis and quantification of COVID-19 by the arrangements of several nanoparticles including gold nanoparticles, iron oxide nanoparticles, etc.
Collapse
|
99
|
Pokrajac L, Abbas A, Chrzanowski W, Dias GM, Eggleton BJ, Maguire S, Maine E, Malloy T, Nathwani J, Nazar L, Sips A, Sone J, van den Berg A, Weiss PS, Mitra S. Nanotechnology for a Sustainable Future: Addressing Global Challenges with the International Network4Sustainable Nanotechnology. ACS NANO 2021; 15:18608-18623. [PMID: 34910476 DOI: 10.1021/acsnano.1c10919] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Nanotechnology has important roles to play in international efforts in sustainability. We discuss how current and future capabilities in nanotechnology align with and support the United Nations' Sustainable Development Goals. We argue that, as a field, we can accelerate the progress toward these goals both directly through technological solutions and through our special interdisciplinary skills in communication and tackling difficult challenges. We discuss the roles of targeting solutions, technology translation, the circular economy, and a number of examples from national efforts around the world in reaching these goals. We have formed a network of leading nanocenters to address these challenges globally and seek to recruit others to join us.
Collapse
Affiliation(s)
- Lisa Pokrajac
- Waterloo Institute for Nanotechnology, University of Waterloo, Mike & Ophelia Lazaridis Quantum Nano Centre, 200 University Avenue W, Waterloo, Ontario N2L 3G1, Canada
| | - Ali Abbas
- The University of Sydney Nano Institute, Camperdown, New South Wales 2006, Australia
| | - Wojciech Chrzanowski
- The University of Sydney Nano Institute, Camperdown, New South Wales 2006, Australia
| | - Goretty M Dias
- Waterloo Institute for Nanotechnology, University of Waterloo, Mike & Ophelia Lazaridis Quantum Nano Centre, 200 University Avenue W, Waterloo, Ontario N2L 3G1, Canada
| | - Benjamin J Eggleton
- The University of Sydney Nano Institute, Camperdown, New South Wales 2006, Australia
| | - Steven Maguire
- The University of Sydney Nano Institute, Camperdown, New South Wales 2006, Australia
| | - Elicia Maine
- Beedie School of Business, Simon Fraser University, 500 Granville Street, Vancouver, British Columbia V6C 1W6, Canada
| | - Timothy Malloy
- University of California, Los Angeles, Los Angeles, California 90095, United States
| | - Jatin Nathwani
- Waterloo Institute for Nanotechnology, University of Waterloo, Mike & Ophelia Lazaridis Quantum Nano Centre, 200 University Avenue W, Waterloo, Ontario N2L 3G1, Canada
| | - Linda Nazar
- Waterloo Institute for Nanotechnology, University of Waterloo, Mike & Ophelia Lazaridis Quantum Nano Centre, 200 University Avenue W, Waterloo, Ontario N2L 3G1, Canada
| | - Adrienne Sips
- National Institute for Public Health and the Environment, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands
| | - Jun'ichi Sone
- Japan Science and Technology Agency, Kawaguchi Center Building, 4 Chome-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan
| | - Albert van den Berg
- MESA+ Institute for Nanotechnology, University of Twente, Hallenweg 15, 7522 NH Enschede, The Netherlands
| | - Paul S Weiss
- California NanoSystems Institute, Department of Chemistry & Biochemistry, Department of Bioengineering, and Department of Materials Science & Engineering, University of California, Los Angeles, Los Angeles, California 90095, United States
| | - Sushanta Mitra
- Waterloo Institute for Nanotechnology, University of Waterloo, Mike & Ophelia Lazaridis Quantum Nano Centre, 200 University Avenue W, Waterloo, Ontario N2L 3G1, Canada
| |
Collapse
|
100
|
Gonzalez A, Aboubakr HA, Brockgreitens J, Hao W, Wang Y, Goyal SM, Abbas A. Durable nanocomposite face masks with high particulate filtration and rapid inactivation of coronaviruses. Sci Rep 2021; 11:24318. [PMID: 34934121 PMCID: PMC8692499 DOI: 10.1038/s41598-021-03771-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 12/06/2021] [Indexed: 02/08/2023] Open
Abstract
The COVID-19 pandemic presents a unique challenge to the healthcare community due to the high infectivity rate and need for effective personal protective equipment. Zinc oxide nanoparticles have shown promising antimicrobial properties and are recognized as a safe additive in many food and cosmetic products. This work presents a novel nanocomposite synthesis approach, which allows zinc oxide nanoparticles to be grown within textile and face mask materials, including melt-blown polypropylene and nylon-cotton. The resulting nanocomposite achieves greater than 3 log10 reduction (≥ 99.9%) in coronavirus titer within a contact time of 10 min, by disintegrating the viral envelope. The new nanocomposite textile retains activity even after 100 laundry cycles and has been dermatologist tested as non-irritant and hypoallergenic. Various face mask designs were tested to improve filtration efficiency and breathability while offering antiviral protection, with Claros' design reporting higher filtration efficiency than surgical masks (> 50%) for particles ranged 200 nm to 5 µm in size.
Collapse
Affiliation(s)
- Andrew Gonzalez
- Claros Technologies Inc., 1000 Westgate Drive, Suite 1005, St. Paul, MN, 55114, USA
| | - Hamada A Aboubakr
- Department of Veterinary Population Medicine, University of Minnesota Twin Cities, 1333 Gortner Ave., St. Paul, MN, 55108, USA
| | - John Brockgreitens
- Claros Technologies Inc., 1000 Westgate Drive, Suite 1005, St. Paul, MN, 55114, USA
| | - Weixing Hao
- Department of Civil, Architectural, and Environmental Engineering, Missouri University of Science and Technology, 1401 N Pine St., Rolla, MO, 65409, USA
| | - Yang Wang
- Department of Civil, Architectural, and Environmental Engineering, Missouri University of Science and Technology, 1401 N Pine St., Rolla, MO, 65409, USA
| | - Sagar M Goyal
- Department of Veterinary Population Medicine, University of Minnesota Twin Cities, 1333 Gortner Ave., St. Paul, MN, 55108, USA
| | - Abdennour Abbas
- Claros Technologies Inc., 1000 Westgate Drive, Suite 1005, St. Paul, MN, 55114, USA.
- Department of Bioproducts and Biosystems Engineering, University of Minnesota-Twin Cities, 2004 Folwell Ave, St. Paul, MN, 55108, USA.
| |
Collapse
|